PF221 MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME

Bone marrow and peripheral blood from 190 newly diagnosed AML patients were included in the NGS study, of which 74 were also ex vivo PM tested. The ex vivo drug profiling was performed by PharmaFlow platform, which preserves bone marrow Native Environment (Bennett T, et al. Clin Lymphoma Myeloma Leuk. 2014). The mutational screening was performed using a custom NGS panel consisting of 32 recurrently mutated genes in myeloid diseases (Onecha E, et al. Haematologica, 2019). Survival curves were calculated according to the Kaplan-Meier method and log-rank test. Multivariate analysis was performed by using Cox regression model. The combination of pharmacological and mutational profiles represents a powerful tool to improve AML patients stratification and could help to select the most suitable treatment for each patient. MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME